Hollenbeck Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Hollenbeck Pharmaceuticals is a private, pre-revenue biotech advancing HOL-101, a synthetic GHRH analog with dual diagnostic and therapeutic applications for Growth Hormone Deficiency. The company has secured Orphan Drug and Rare Pediatric Disease designations from the FDA and has completed a Pre-IND meeting, receiving written guidance on its development plan. With a strategy to potentially bring the diagnostic to market first, Hollenbeck is actively seeking collaboration and investment partners to advance the program in a global GHD market estimated at over $5 billion.

EndocrinologyGrowth Hormone Deficiency

Technology Platform

Synthetic Growth Hormone-Releasing Hormone (GHRH) 1-44 amide analog platform for dual diagnostic and therapeutic use.

Opportunities

The primary opportunity lies in addressing a $5+ billion GHD market with a first-in-class dual diagnostic/therapeutic.

Orphan drug designations provide market exclusivity and a faster regulatory pathway.

A successful diagnostic could redefine the standard of care and expand the treatable patient population.

Risk Factors

Key risks include clinical failure of the novel HOL-101 compound, inability to secure necessary funding or partnerships for development, and intense competition from established recombinant growth hormone therapies in the treatment market.

Competitive Landscape

The GHD therapeutic market is dominated by large pharma companies selling recombinant human growth hormone (e.g., Pfizer, Novo Nordisk, Roche). The diagnostic landscape is fragmented with older stimulation tests. Hollenbeck's unique proposition is a single molecule targeting both areas, potentially offering a more physiological therapeutic and a more reliable diagnostic.

More companies in United States →